Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Leflunomide and Prednisone in Progressive IgA Nephropathy
NCT04020328Phase 4Unknown
- Sponsor
- Shenzhen Second People's Hospital
- Start
- Sep 2019
- Primary completion
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of leflunomide in IgA nephropathy (IgAN), sponsored by Shenzhen Second People's Hospital. Primary endpoint: Renal survival rate at 96 weeks. Status: unknown.
02
Drugs
leflunomide
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on NCT04020328.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04020328.